EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 961 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 Can Getting a “Base Tan” Protect You From Sunburn and Skin... March 30, 2023 ESMO Clinical Practice Guideline Express Update on the management of epithelial... January 28, 2026 Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients... September 21, 2026 Load more HOT NEWS Making Important Decisions During Cancer: A Survivor’s Story Cancer in My Community: Reducing Tobacco Use in Tunisia To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults...
